Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P860003/S112

THERAKOS CELLEX Photopheresis System (CELLEX), THERAKOS CELLEX Photopheresis Procedural Kit (CLXUSA and CLXECP), THE

THERAKOS DEVELOPMENT LIMITED · Decision date Nov 21, 2025

FDA DECISIONP860003/S112

What did the FDA approve?

FDA records P860003/S112 as a supplement to PMA P860003, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 21, 2025.

FDA approval order statement

Approval for manufacturing changes to the blood and air filter component of the pump tubing organizer in the THERAKOS CELLEX Procedural Kit wherein the raw material supplier is changed, and the washing line equipment is updated.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Gastroenterology, Urology
Decision date
Nov 21, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P860003/S112
Regulatory pathway
PMA supplement
Product code
LNR
Decision code
APPR
Decision date
Nov 21, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, photopheresis, extracorporeal.

Product code
LNR
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P860003/S112 received

    Application receipt date recorded by FDA.

  2. P860003/S112 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P860003. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

THERAKOS DEVELOPMENT LIMITED

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
College Business & Technology Park, Cruiserath Rd., Dublin, D15 TX2V

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records